Molecular mechanisms of preeclampsia

Lyashenko E.N.; Saenko J.S.

doi:https://doi.org/10.17116/repro20253102144

Рекомендуем статьи по данной теме:

Влияние биопсии трофэктодермы на течение беременности и акушерские исходы. Проблемы репродукции. 2025;(3):63-69

Уровень фактора-1α, индуцируемого гипоксией, и ассоциированных с ним молекул при преэклампсии. Российский вестник акушера-гинеколога. 2025;(1):5-10

Современные представления о преэклампсии с учетом роли проницаемости гематоэнцефалического барьера. Российский вестник акушера-гинеколога. 2025;(1):11-18

Морфологические маркеры митохондриальной дисфункции цитотрофобласта базальной пластинки плаценты при преэклампсии разной степени тяжести. Архив патологии. 2025;(2):24-29

Сравнительный анализ протеома плаценты в норме и при тяжелой преэклампсии. Российский вестник акушера-гинеколога. 2025;(5):5-14

Резюме / Abstract:

В последние годы проведены исследования, указывающие на связь между преэклампсией (ПЭ) и дисбалансом ангиогенных факторов. Этот дисбаланс приводит к нарушению функции эндотелия, в результате чего возникает ПЭ. Преэклампсия связана с нарушением инвазии плацентарного цитотрофобласта и ремоделирования спиральных артерий. Это затрудняет нормальную перфузию плаценты, в ответ организм вырабатывает воспалительные и антиангиогенные факторы, которые в больших количествах присутствуют в материнской крови при ПЭ. Факторы, к которым относятся плацентарный фактор роста (PGF), растворимая fms-подобная тирозинкиназа-1 (sFlt-1) и плацентарный белок 13, считаются частью этого процесса. Они могут повреждать стенки сосудов матери, в некоторых случаях — органы, вызывать эндотелиальную дисфункцию, повышение уровня артериального давления и обусловливать материнскую смертность. Определение уровня плацентарных биомаркеров облегчает своевременное установление диагноза ПЭ и назначение соответствующего лечения. Информация, представленная в данной статье, помогает лучше понять механизмы развития ПЭ, но важно, что это сложное состояние, при развитии которого требуется медицинское вмешательство и наблюдение.

Ключевые слова / Keywords:

преэклампсия

ангиогенные факторы

плацентарный фактор роста

растворимая fms-подобная тирозинкиназа-1

плацентарный белок 13

Авторы / Authors:

Ляшенко Е.Н.

ФГАОУ ВО «Крымский федеральный университет имени В.И. Вернадского» Минобрнауки России

ORCID: 0000-0002-4350-5020

Саенко Ю.С.

ФГАОУ ВО «Крымский федеральный университет имени В.И. Вернадского» Минобрнауки России

ORCID: 0000-0002-5304-6112

Дата поступления:

07.09.2023

Дата принятия в печать:

21.01.2024

Закрыть метаданные

Литература / References:

Magee LA, Brown MA, Hall DR, Gupte S, Hennessy A, Karumanchi SA, Kenny LC, McCarthy F, Myers J, Poon LC, Rana S, Saito S, Staff AC, Tsigas E, von Dadelszen P. The 2021 International Society for the Study of Hypertension in Pregnancy classification, diagnosis & management recommendations for international practice. Hypertension in Pregnancy. 2022;27:148-169. https://doi.org/10.1016/j.preghy.2021.09.008
Gyselaers W. Preeclampsia Is a Syndrome with a Cascade of Pathophysiologic Events. Journal of Clinical Medicine. 2020;9(7). https://doi.org/10.3390/jcm9072245
Aneman I, Pienaar D, Suvakov S, Simic TP, Garovic VD, McClements L. Mechanisms of Key Innate Immune Cells in Early- and Late-Onset Preeclampsia. Frontiers in Immunology. 2020;11. https://doi.org/10.3389/fimmu.2020.01864
Apicella C, Ruano C, Méhats C, Miralles F, Vaiman D. The Role of Epigenetics in Placental Development and the Etiology of Preeclampsia. The International Journal of Molecular Sciences. 2019; 20:2837. https://doi.org/10.3390/ijms20112837
Huppertz B. Biology of preeclampsia: Combined actions of angiogenic factors, their receptors and placental proteins. Biochimica et Biophysica Acta. Molecular Basis of Disease. 2020:2020;1866. https://doi.org/10.1016/j.bbadis.2018.11.024
Townsend R, O’Brien P, Khalil A. Current best practice in the management of hypertensive disorders in pregnancy. Integrated Blood Pressure Control. 2016;9:79-94. https://doi.org/10.2147/IBPC.S77344
Bellamy L, Casas JP, Hingorani AD, Williams DJ. Pre-eclampsia and risk of cardiovascular disease and cancer in later life: a systematic review and meta-analysis. British Medical Journal. 2007;335:974-977. https://doi.org/10.1136/bmj.39335.385301.BE
American College of Obstetricians and Gynecologists. Task Force on Hypertension in Pregnancy. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists’ Task Force on Hypertension in Pregnancy. Obstetrics and Gynecology. 2013;122(5):1122-1131. https://doi.org/10.1097/01.AOG.0000437382.03963.88
Phipps EA, Thadhani R, Benzing T, Karumanchi SA. Pre-eclampsia: pathogenesis, novel diagnostics and therapies. Nature Reviews Nephrology. 2019;15(5):275-289. https://doi.org/10.1038/s41581-019-0119-6
Brosens I, Puttemans P, Benagiano G. Placental bed research: I. The placental bed: From spiral arteries remodeling to the great obstetrical syndromes. American Journal of Obstetrics and Gynecology. 2019;221:437-456. https://doi.org/10.1016/j.ajog.2019.05.044
Mutter WP, Karumanchi SA. Molecular mechanisms of preeclampsia. Microvascular Research. 2008;75:1-8. https://doi.org/10.1016/j.mvr.2007.04.009
Matyas M, Hasmasanu M, Silaghi CN, Samasca G, Lupan I, Orsolya K, Zaharie G. Early Preeclampsia Effect on Preterm Newborns Outcome. Journal of Clinical Medicine. 2022;11(2):452. https://doi.org/10.3390/jcm11020452
Shear RM, Rinfret D, Leduc L. Should we offer expectant management in cases of severe preterm preeclampsia with fetal growth restriction? American Journal of Obstetrics and Gynecology. 2005;192: 1119-1125. https://doi.org/10.1016/j.ajog.2004.10.621
Weiler J, Tong S, Palmer KR. Is fetal growth restriction associated with a more severe maternal phenotype in the setting of early onset pre-eclampsia? A retrospective study. PLoS One. 2011;6(10):0026937. https://doi.org/10.1371/journal.pone.0026937
Verlohren S, Melchiorre K, Khalil A, Thilaganathan B. Uterine artery Doppler, birth weight and timing of onset of pre-eclampsia: providing insights into the dual etiology of late-onset preeclampsia. Ultrasound in Obstetrics and Gynecology. 2014;44(3):293-298. https://doi.org/10.1002/uog.13310
Chang KJ, Seow KM, Chen KH. Preeclampsia: Recent Advances in Predicting, Preventing, and Managing the Maternal and Fetal Life-Threatening Condition. International Journal of Environmental Research and Public Health. 2023;20(4):2994. https://doi.org/10.3390/ijerph20042994
Perry H, Khalil A, Thilaganathan B. New aspects on the etiology of preeclampsia. Preeclampsia and the cardiovascular system: An update. Trends in Cardiovascular Medicine. 2018;28(8):505-513. https://doi.org/10.1016/j.tcm.2018.04.009
Pereira MM, Torrado J, Sosa C, Zócalo Y, Bia D. Role of arterial impairment in preeclampsia: should the paradigm shift? American Journal of Physiology — Heart and Circulatory Physiology. 2021; 320(5):H2011-H2030. https://doi.org/10.1152/ajpheart.01005.2020
Turbeville HR, Sasser JM. Preeclampsia beyond pregnancy: Long-term consequences for mother and child. American Journal of Physiology. 2020;318:F1315-F1326. https://doi.org/10.1152/ajprenal.00071.2020
Sławek-Szmyt S, Kawka-Paciorkowska K, Ciepłucha A, Lesiak M, Ropacka-Lesiak M. Preeclampsia and Fetal Growth Restriction as Risk Factors of Future Maternal Cardiovascular Disease — A Review. Journal of Clinical Medicine. 2022;11. https://doi.org/10.3390/jcm11206048
Wang Y, Li B, Zhao Y. Inflammation in Preeclampsia: Genetic Biomarkers, Mechanisms, and Therapeutic Strategies. Frontiers in Immunology. 2022;13:883404. https://doi.org/10.3389/fimmu.2022.883404
Opichka MA, Rappelt MW, Gutterman DD, Grobe JL, McIntosh JJ. Vascular Dysfunction in Preeclampsia. Cells. 2021;10(11):3055. https://doi.org/10.3390/cells10113055
Brownfoot FC, Hannan NJ, Cannon P, Nguyen V, Hastie R, Parry LJ, Senadheera S, Tuohey L, Tong S, Kaitu’u-Lino TJ. Sulfasalazine reduces placental secretion of antiangiogenic factors, up-regulates the secretion of placental growth factor and rescues endothelial dysfunction. EBioMedicine. 2019;41:636-648. https://doi.org/10.1016/j.ebiom.2019.02.013
Wang J, Zhu QW, Cheng XY, Liu JY, Zhang LL, Tao YM, Cui YB, Wei Y. Assessment efficacy of neutrophil-lymphocyte ratio and monocyte-lymphocyte ratio in preeclampsia. American Journal of Reproductive Immunology. 2019;132:29-34. https://doi.org/10.1016/j.jri.2019.02.001
Ma Y, Ye Y, Zhang J, Ruan C.-C, Gao P.-J. Immune imbalance is associated with the development of preeclampsia. Medicine (Baltimore). 2019;98:0000000000015080. https://doi.org/10.1097/MD.0000000000015080
Dimitriadis E, Rolnik DL, Zhou W, Estrada-Gutierrez G, Koga K, Francisco RPV, Whitehead C, Hyett J, da Silva Costa F, Nicolaides K, Menkhorst E. Pre-eclampsia. Nature Reviews Disease Primers. 2023;9(1):8. https://doi.org/10.1038/s41572-023-00417-6
Tabacco S, Ambrosii S, Polsinelli V, Fantasia I, D’Alfonso A, Ludovisi M, Cecconi S, Guido M. Pre-Eclampsia: From Etiology and Molecular Mechanisms to Clinical Tools — A Review of the Literature. Current Issues in Molecular Biology. 2023;45:6202-6215. https://doi.org/10.3390/cimb45080391
Dymara-Konopka W, Laskowska M, Blazewicz A. Angiogenic imbalance as a contributor of preeclampsia. Current Pharmaceutical Biotechnology. 2018;19(10):797-815. https://doi.org/10.2174/1389201019666180925115559
Rybak-Krzyszkowska M, Staniczek J, Kondracka A, Bogusławska J, Kwiatkowski S, Góra T, Strus M, Górczewski W. From Biomarkers to the Molecular Mechanism of Preeclampsia-A Comprehensive Literature Review. The International Journal of Molecular Sciences. 2023;24(17):13252. https://doi.org/10.3390/ijms241713252
Failla CM, Carbo M, Morea V. Positive and negative regulation of angiogenesis by soluble vascular endothelial growth factor receptor-1. International Journal of Molecular Sciences. 2018;19:1306-1322. https://doi.org/10.3390/ijms19051306
Cianfarani F, Zambruno G, Brogelli L, Sera F, Lacal PM, Pesce M, Capogrossi MC, Failla CM, Napolitano M, Odorisio T. Placenta growth factor in diabetic wound healing: altered expression and therapeutic potential. The American Journal of Pathology. 2006; 169:1167-1182. https://doi.org/10.2353/ajpath.2006.051314
Gonzales SK, Badell M, Cottrell H, Rimawi B, Deepak V, Sidell N, Rajakumar A. Villous explants from preeclamptic placentas induce sFlt1 in PBMCs: An ex vivo co-culture study. Hypertension in Pregnancy. 2018;12:40-46. https://doi.org/10.1016/j.preghy.2018.02.006
Pimentel AM, Pereira NR, Costa CA, Mann GE, Cordeiro VSC, de Moura RS, Brunini TMC, Mendes-Ribeiro AC, Resende AC. L-arginine-nitric oxide pathway and oxidative stress in plasma and platelets of patients with pre-eclampsia. Hypertension Research. 2013;36:783-788. https://doi.org/10.1038/hr.2013.34
Zeng Y, Li M, Chen Y, Wang S. Homocysteine, endothelin-1 and nitric oxide in patients with hypertensive disorders complicating pregnancy. The International Journal of Clinical and Experimental Pathology. 2015;8:15275-15279.
Robertson SA. Preventing Preeclampsia by Silencing Soluble Flt-1? The New England Journal of Medicine. 2019;380:1080-1082. https://doi.org/10.1056/NEJMcibr1817501
Marshall SA, Hannan NJ, Jelinic M, Nguyen TPH, Girling JE, Parry LJ. Animal models of preeclampsia: Translational failings and why. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology. 2018;314:R499-R508. https://doi.org/10.1152/ajpregu.00355.2017
Kim MW, Hong SC, Choi JS, Han J-Y, Oh M-J, Kim HJ, Nava-Ocampo A, Koren G. Homocysteine, folate and pregnancy outcomes. Journal of Obstetrics and Gynaecology. 2012;32:520-524. https://doi.org/10.3109/01443615.2012.693984
Dekker AG, DeVries JIP, Doelitzsch PM, Huijgens PC, von Blomberg BM, Jakobs C, van Geijn HP. Underlying disorders associated with severe early onset preeclampsia. American Journal of Obstetrics and Gynecology. 1995;173:1042-1048. https://doi.org/10.1016/0002-9378(95)91324-6
Maged AM, Saad H, Meshaal H, Salah E, Abdelaziz S, Omran E, Deeb WS, Katta M. Maternal serum homocysteine and uterine artery Doppler as predictors of preeclampsia and poor placentation. Archives of Gynecology and Obstetrics. 2017;296:475-482. https://doi.org/10.1007/s00404-017-4609-0
Dymara-Konopka W, Laskowska M. The Role of Nitric Oxide, ADMA, and Homocysteine in The Etiopathogenesis of Preeclampsia — Review. The International Journal of Molecular Sciences. 2019;20:2757. https://doi.org/10.3390/ijms20112757
Herrmann W, Isber S, Obeid R, Herrmann M, Jouma M. Concentrations of homocysteine, related metabolites and asymmetric dimethylarginine in preeclamptic women with poor nutritional status. Clinical Chemistry and Laboratory Medicine. 2005;43:1139-1146. https://doi.org/10.1515/CCLM.2005.198
Veldman BA, Vervoort G, Blom H, Smits P. Reduced plasma total homocysteine concentrations in Type 1 diabetes mellitus is determined by increased renal clearance. Diabetic Medicine. 2005;22:301-305. https://doi.org/10.1111/j.1464-5491.2005.01415.x
Liang B, Wang X, Zhang N, Yang H, Bai R, Liu M, Bian Y, Xiao C, Yang Z. Angiotensin-(1-7) attenuates angiotensin II-induced ICAM-1, VCAM-1, and MCP-1 expression via the MAS receptor through suppression of P38 and NF-κB pathways in HUVECs. Cellular Physiology and Biochemistry. 2015;35:2472-2482. https://doi.org/10.1159/000374047
Virtanen A, Huttala O, Tihtonen K, Toimela T, Heinonen T, Uotila J. Angiogenic capacity in pre-eclampsia and uncomplicated pregnancy estimated by assay of angiogenic proteins and an in vitro vasculogenesis/angiogenesis test. Angiogenesis. 2018;22(1):67-74. https://doi.org/10.1007/s10456-018-9637-2
Litwińska E, Litwińska M, Oszukowski P, Szaflik K, Kaczmarek P. Combined screening for early and late pre-eclampsia and intrauterine growth restriction by maternal history, uterine artery Doppler, mean arterial pressure and biochemical markers. Advances in Clinical and Experimental Medicine. 2017;26:439-448. https://doi.org/10.17219/acem/62214
Poon LC, Lesmes C, Gallo DM, Akolekar R, Nicolaides KH. Prediction of small for-gestational-age neonates: screening by biophysical and biochemical markers at 19-24 weeks. Ultrasound in Obstetrics and Gynecology. 2015;46:437-445. https://doi.org/10.1002/uog.14904
Ukah UV, Hutcheon JA, Payne B, Haslam MD, Vatish M, Ansermino JM, Brown H, Magee LA, von Dadelszen P. Placental growth factor as a prognostic tool in women with hypertensive disorders of pregnancy: a systematic review. Hypertension. 2017;70:1228-1237. PMID: 29084878; PMCID: PMC5680987. https://doi.org/10.1161/HYPERTENSIONAHA.117.10150
Meng Q, Duan P, Li L, Miao Y. Expression of placenta growth factor is associated with unfavorable prognosis of advanced-stage serous ovarian cancer. The Tohoku Journal of Experimental Medicine. 2018;244(4):291-296. https://doi.org/10.1620/tjem.244.291
Dumnicka P, Sporek M, Mazur-Laskowska M, Ceranowicz P, Kuźniewski M, Drożdż R, Ambroży T, Olszanecki R, Kuśnierz-Cabala B. Serum soluble Fms-like tyrosine kinase 1 (sFlt-1) predicts the severity of acute pancreatitis. The International Journal of Molecular Sciences. 2016;17:2038. https://doi.org/10.3390/ijms17122038
Chelli D, Hamdi A, Saoudi S, Zagre A, Jguerim H, Bedis C, Sfar E. Clinical assessment of soluble FMS-like tyrosine kinase-1/placental growth factor ratio for the diagnostic and the prognosis of preeclampsia in the second trimester. Clinical Laboratory. 2016;62:1927-1932. PMID: 28164532. https://doi.org/10.7754/Clin.Lab.2016.151004
Ridder A, Giorgione V, Khalil A, Thilaganathan B. Preeclampsia: The Relationship between Uterine Artery Blood Flow and Trophoblast Function. The International Journal of Molecular Sciences. 2019;20:3263. https://doi.org/10.3390/ijms20133263
Dewerchin M, Carmeliet P. PlGF: a multitasking cytokine with disease-restricted activity. Cold Spring Harbor Perspectives in Medicine. 2012;2(8):011056. https://doi.org/10.1101/cshperspect.a011056
Sammar M, Drobnjak T, Mandala M, Gizurarson S, Huppertz B, Meiri H. Galectin 13 (PP13) Facilitates Remodeling and Structural Stabilization of Maternal Vessels during Pregnancy. The International Journal of Molecular Sciences. 2019;20:3192. https://doi.org/10.3390/ijms20133192
Sammar M, Dragovic R, Meiri H, Vatish M, Sharabi-Nov A, Sargent I, Redman C, Tannetta D. Reduced placental protein 13 (PP13) in placental derived syncytiotrophoblast extracellular vesicles in preeclampsia — a novel tool to study the impaired cargo transmission of the placenta to the maternal organs. Placenta. 2018;66:17-25. https://doi.org/10.1016/j.placenta.2018.04.013
Huppertz B, Sammar M, Chefetz I, Neumaier-Wagner P, Bartz C, Meiri H. Longitudinal determination of serum placental protein 13 during development of preeclampsia. Fetal Diagnosis and Therapy. 2008;24:230-236. https://doi.org/10.1159/000151344
Huppertz B, Meiri H, Gizurarson S, Osol G, Sammar M. Placental protein 13 (PP13): a new biological target shifting individualized risk assessment to personalized drug design combating pre-eclampsia. Human Reproduction Update. 2013;19:391-405. https://doi.org/10.1093/humupd/dmt003
Drobnjak T, Jónsdóttir AM, Helgadóttir H, Runólfsdóttir MS, Meiri H, Sammar M, Osol G, Mandalà M, Huppertz B, Gizurarson S. Placental protein 13 (PP13) stimulates rat uterine vessels after slow subcutaneous administration. Drug Design, Development and Therapy. 2018;11:213-222. https://doi.org/10.2147/IJWH.S188303
Spiezia L, Bogana G, Campello E, Maggiolo S, Pelizzaro E, Carbonare CD, Gervasi MT, Simioni P. Whole blood thromboelastometry profiles in women with preeclampsia. Clinical Chemistry and Laboratory Medicine. 2015;53:1793-1798. https://doi.org/10.1515/cclm-2014-1128
Honkura N, Richards M, Laviña B, Sáinz-Jaspeado M, Betsholtz C, Claesson-Welsh L. Intravital imaging-based analysis tools for vessel identification and assessment of concurrent dynamic vascular events. Nature Communications. 2018;9(1):2746. https://doi.org/10.1038/s41467-018-04929-8